Advertisement

Journal of General Internal Medicine

, Volume 33, Issue 2, pp 155–165 | Cite as

Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease

  • Zachary A. Marcum
  • Christopher W. Forsberg
  • Kathryn P. Moore
  • Ian H. de Boer
  • Nicholas L. Smith
  • Edward J. Boyko
  • James S. Floyd
Article

Abstract

Background

For patients with type 2 diabetes and chronic kidney disease (CKD), high-quality evidence about the relative benefits and harms of oral glucose-lowering drugs is limited.

Objective

To evaluate whether mortality risk differs after the initiation of monotherapy with either metformin or a sulfonylurea in Veterans with type 2 diabetes and CKD.

Design

Observational, national cohort study in the Veterans Health Administration (VHA).

Participants

Veterans who received care from the VHA for at least 1 year prior to initiating monotherapy treatment for type 2 diabetes with either metformin or a sulfonylurea between 2004 and 2009.

Main Measures

Metformin and sulfonylurea use was assessed from VHA electronic pharmacy records. The CKD-EPI equation was used to estimate glomerular filtration rate (eGFR). The outcome of death from January 1, 2004, through December 31, 2009, was assessed from VHA Vital Status files.

Key Results

Among 175,296 new users of metformin or a sulfonylurea monotherapy, 5121 deaths were observed. In primary analyses adjusted for all measured potential confounding factors, metformin monotherapy was associated with a lower mortality hazard ratio (HR) compared with sulfonylurea monotherapy across all ranges of eGFR evaluated (HR ranging from 0.59 to 0.80). A secondary analysis of mortality risk differences favored metformin across all eGFR ranges; the greatest risk difference was observed in the eGFR category 30–44 mL/min/1.73m2 (12.1 fewer deaths/1000 person-years, 95% CI 5.2–19.0).

Conclusions

Initiation of metformin versus a sulfonylurea among individuals with type 2 diabetes and CKD was associated with a substantial reduction in mortality, in terms of both relative and absolute risk reduction. The largest absolute risk reduction was observed among individuals with moderately–severely reduced eGFR (30–44 mL/min/1.73m2).

KEY WORDS

diabetes chronic kidney disease mortality 

INTRODUCTION

Metformin, along with diet and exercise, is the first-line glucose-lowering treatment for patients with type 2 diabetes.1 At the time of its approval by the Food and Drug Administration (FDA) in 1995, metformin carried a contraindication based on serum creatinine levels due to fears about lactic acidosis caused by an older biguanide drug, phenformin.2 This contraindication led to avoidance of metformin use in many patients with renal insufficiency.3 In April 2016, the FDA changed the measure of kidney function used to determine whether patients could receive metformin, from a serum creatinine-based approach to one based on the estimated glomerular filtration rate (eGFR), which provides a more accurate assessment of renal function (Appendix Figure 3).4 The FDA concluded that metformin could be used safely in patients with mild impairment in kidney function and in some patients with moderate impairment.

Given this expanded eligibility for metformin therapy, and given the increasing burden of chronic kidney disease (CKD) in patients with diabetes,5 evidence is needed regarding the relative benefits and harms of metformin therapy in this population. While no randomized controlled trials have addressed this question, observational studies have examined metformin use and health outcomes in CKD populations.6 11 A recent systematic review identified major limitations in the design of these prior studies, including a lack of a well-defined comparator group to metformin, an assessment of medication use at baseline rather than during follow-up, and the inclusion of prevalent users rather than new users of diabetes therapies.12

In an observational cohort of Veterans with type 2 diabetes and CKD who received regular healthcare from the Veterans Health Administration (VHA), we evaluated whether mortality risk differed after the initiation of monotherapy with either metformin or a sulfonylurea, the second most commonly prescribed class of oral glucose-lowering drugs after metformin.13 We sought to address some of the key limitations of prior studies. This analysis was conducted using data from 2003 to 2009, a period of clinical equipoise regarding the choice of metformin or sulfonylureas when initiating treatment for type 2 diabetes.14

METHODS

Setting and Data Sources

The VHA uses a uniform national electronic medical record that captures information from all instances of medical care delivered in its facilities and prescriptions filled in its pharmacies. Demographic, comorbidity, laboratory, and medication use data from January 1, 2003, to December 31, 2009, were obtained from the VHA national medical and pharmacy data housed at the Austin Information Technology Center. Race/ethnicity was determined from administrative data, which was based on self-report. The presence of comorbidities at baseline was identified using International Classification of Diseases, Ninth Revision (ICD-9) codes from outpatient encounters at VHA facilities that occurred within the year before initiation of diabetes therapy (Appendix Table 4). In a previous validation study, we found that ICD-9 code-based algorithms had moderate to good accuracy for identifying cardiovascular conditions and cardiovascular risk factors.15 For laboratory tests, only the most recent values within the year before initiation of diabetes therapy were used. Prescription records included drug name, quantity, number of days dispensed, and fill date. Weight was calculated as the median value of all measures obtained during the year in which the oral hypoglycemic medication was initiated, while height was taken as the median of all values. Body mass index (BMI) was calculated as weight (kg)/height (m)2. The VA Puget Sound Health Care System Institutional Review Board reviewed and approved this research.

Study Participants and Eligibility Criteria

This was a new-user, national cohort study of Veterans with type 2 diabetes and CKD who received healthcare from the VHA and initiated monotherapy with either metformin or a sulfonylurea. A previous study reported on the comparative safety of glucose-lowering drugs among persons in this cohort without CKD, using similar methods.16 Veterans enrolled in the VHA who received at least two consecutive prescriptions for metformin or a sulfonylurea within a period of 180 days, between January 1, 2003 and December 31, 2009, were eligible for this analysis. Follow-up of patients began on the date of the second prescription. This time frame was chosen because, during that period, a state of clinical equipoise existed regarding initiation of treatment for type 2 diabetes with either metformin or sulfonylureas (Appendix Table 5). The CKD-EPI Equation was used to estimate GFR, and individuals were classified according to eGFR categories.17 , 18

To capture only new users of metformin or a sulfonylurea, we excluded Veterans who used any glucose-lowering drugs (including insulin) before their first prescription for metformin or a sulfonylurea during the time period of interest. We also excluded Veterans who did not have prescriptions for non-diabetes medications obtained from VHA during the year before the first prescription for metformin or a sulfonylurea, because for these individuals we could not distinguish whether they were new users of oral diabetes therapies or prevalent users who had filled previous prescriptions for diabetes medications outside the VHA. To restrict our analysis to a population likely to be receiving care and medications from the VHA, we also excluded persons who did not have an outpatient visit to a VHA facility in the year before the first prescription for metformin or a sulfonylurea. In addition, we excluded patients with missing values for baseline serum creatinine and race, both of which are needed to estimate eGFR. Lastly, those with an eGFR of <30 mL/min/1.73m2 were excluded due to the small sample size.

Assessment of Medication Use

Individuals were categorized as initiators of metformin or a sulfonylurea at the time of cohort entry based on VHA prescriptions dispensed. The period of exposure for a given prescription started on the date the medication was dispensed and lasted for a period of time equal to 1.25 times the days' supply, plus 90 days.16 During follow-up, if another prescription for the same medication was not filled by the end of this period, it was assumed that the medication was discontinued at the end of the exposure period. Use of diabetes treatments other than metformin and sulfonylureas was captured to identify a change in treatment to another monotherapy or combination therapy. Individuals were censored at the time they discontinued their baseline diabetes treatment (metformin or sulfonylurea monotherapy) or received a prescription for a diabetes medication other than their baseline treatment.

Outcome Measure

The primary outcome was all-cause mortality. Mortality status was ascertained for the period from January 1, 2004, to December 31, 2009, using VA Vital Status files. These files have been shown to be accurate compared to the National Death Index.19

Statistical Analysis

Primary Analysis

Mortality incidence rates and 95% confidence intervals (CIs) were estimated for each treatment group by eGFR category. Unadjusted relative risk for metformin use compared with sulfonylurea use was estimated from these incidence rates. For the primary analysis, we used Cox regression to estimate hazard ratios (HRs) for mortality associated with initiation of metformin versus sulfonylurea monotherapy. The proportional hazards assumption was examined by visually inspecting log–log plots, which were parallel and thus did not violate the assumption. Individuals were censored at the first occurrence of any of the following events: death, discontinuation of initial monotherapy, initiation of any other diabetes medication, or end of study on December 31, 2009. We selected covariates for adjustment a priori to reduce measured confounding by factors that might be associated with both mortality and the initial choice in prescribing metformin or sulfonylurea monotherapy. We adjusted for the following groups of covariates: demographic variables, health behaviors, eGFR category, comorbid conditions, laboratory values, and cardiovascular medication use. The VA is divided into 21 geographic areas, called Veterans Integrated Service Networks (VISN), which we adjusted for. Multiple imputation was conducted for those missing HDL, LDL, or A1c values (missingness: 8%, 12%, and 12%, respectively) with 50 replications of the analytical data set.20 An interaction term was estimated for each treatment-by-eGFR category compared with the eGFR category ≥90 mL/min/1.73m2.

Sensitivity analyses were conducted to assess the robustness of the primary analysis. First, complete adherence to initial monotherapy was assumed regardless of failure to refill the medication after cohort entry or the addition of a second glucose-lowering medication; this is similar to an intention-to-treat analysis of a clinical trial.21 Second, a complete-case analysis was conducted by excluding those with missing data on HDL, LDL, or A1c values.

Secondary Analyses

Cox regression was used to estimate HRs for mortality associated with initiation of metformin versus sulfonylurea monotherapy among various subgroups (age < 65 vs. ≥65 years; age < 75 vs. ≥75 years; BMI <30 vs. ≥30; previous cardiovascular disease; and previous congestive heart failure) within each eGFR category, with adjustment for the same variables as in the primary analyses and using multiple imputation to handle missing HDL, LDL, or A1c values. Interaction terms were estimated for each subgroup between treatment and eGFR categories. To evaluate absolute differences in mortality rates associated with metformin versus sulfonylurea monotherapy, we estimated adjusted incidence rates for mortality by treatment group and eGFR category using Poisson regression. We then calculated adjusted risk differences, comparing individuals receiving metformin with those receiving a sulfonylurea, and used a bootstrap analysis of 100 samples to estimate 95% CIs.22 Unadjusted Kaplan–Meier curves were generated by eGFR category. All statistical analyses were conducted with Stata (version 15.0; StataCorp LLC, College Station, TX, USA).

RESULTS

Characteristics of the Study Population

Of the 769,126 subjects who received a prescription for an oral glucose-lowering medication from January 1, 2004, to December 31, 2009, 175,296 initiators of metformin or sulfonylurea monotherapy met eligibility criteria for the cohort study (Fig. 1 ). Characteristics of participants at the time of cohort entry are shown in Table 1. Metformin initiators were on average younger, had a higher BMI, and had a lower prevalence of cardiovascular disease than sulfonylurea initiators. In addition, metformin initiators had higher eGFRs and slightly lower A1c values than sulfonylurea initiators.
Figure 1

Eligibility criteria and sample size.

Table 1

Baseline Characteristics of 175,296 Veterans Who Initiated Monotherapy with Metformin or a Sulfonylurea, Veterans Health Administration, 2004–2009

 

Metformin

Sulfonylurea

N = 111,781

N = 63,515

Demographics, n (%)

 Mean age, years (SD)

64.1 (10.3)

67.8 (11.2)

 Male

107,645 (96.3)

62,192 (97.9)

 Race

  White

92,986 (83.2)

51,862 (81.6)

  Black

14,607 (13.1)

9453 (14.9)

  Other

4188 (3.7)

2200 (3.5)

Health behavior, n (%)

 BMI

   < 25

8246 (7.5)

7434 (11.9)

  25–29.9

32,623 (29.6)

21,725 (34.8)

  30–34.9

36,888 (33.5)

19,522 (31.3)

  35–39.9

20,133 (18.3)

8958 (14.4)

  40+

12,330 (11.2)

4738 (7.6)

 Tobacco use diagnosis

28,723 (25.7)

14,655 (23.1)

 Alcohol diagnosis

4265 (3.8)

2300 (3.6)

Estimated glomerular filtration rate (eGFR), n (%)

 Mean eGFR, mL/min/1.73m2 (SD)

78.4 (16.6)

68.1 (20.7)

 eGFR category (mL/min/1.73m2)

   ≥ 90

28,667 (25.7)

10,797 (17.0)

  60–89

67,541 (60.4)

27,948 (44.0)

  45–59

14,407 (12.9)

15,635 (24.6)

  30–44

1166 (1.0)

9135 (14.4)

Comorbid conditions*, n (%)

 Hypertension

85,891 (76.8)

49,293 (77.6)

 Hyperlipidemia

68,405 (61.2)

35,581 (56.0)

 Acute myocardial infarction

299 (0.3)

222 (0.4)

 Myocardial infarction

2485 (2.2)

1842 (2.9)

 Stable angina

19,864 (17.8)

14,751 (23.2)

 Other coronary artery disease

14,457 (12.9)

9868 (15.5)

 Congestive heart failure

4801 (4.3)

6219 (9.8)

 Peripheral vascular disease

6628 (5.9)

5360 (8.4)

 Cerebrovascular disease

6780 (6.1)

5124 (8.1)

 Neuropathy

1883 (1.7)

1391 (2.2)

 Retinopathy

1833 (1.6)

1551 (2.4)

 Diabetic foot ulcer

499 (0.5)

377 (0.6)

Laboratory results

 Mean HDL cholesterol, mg/dL (SD)

39.4 (11.2)

39.4 (12.1)

 Mean LDL cholesterol, mg/dL (SD)

99.2 (35.6)

97.0 (36.0)

 Mean creatinine, mg/dL (SD)

1.0 (0.2)

1.2 (0.3)

 Mean hemoglobin A1c, % (SD)

7.2 (2.9)

7.4 (2.9)

Cardiovascular medications, n (%)

 Nitrates

12,948 (11.6)

10,205 (16.0)

 Thiazide diuretic

26,601 (23.8)

14,187 (22.3)

 Loop diuretic

12,165 (10.9)

12,831 (20.2)

 Potassium-sparing diuretic

6300 (5.6)

5335 (8.4)

 Calcium channel blocker

27,832 (24.9)

17,974 (28.3)

 Beta-blocker

45,142 (40.4)

29,222 (46.0)

 ACE inhibitor

52,356 (46.8)

31,670 (49.9)

 Angiotensin receptor blocker

8470 (7.6)

4956 (7.8)

 Cardiac glycosides

4475 (4.0)

5467 (8.6)

 Statin

74,572 (66.7)

39,905 (62.8)

 Fibrates

11,326 (10.1)

6013 (9.5)

 Aspirin

18,032 (16.1)

10,741 (16.9)

 Other antiplatelet

7503 (6.7)

5624 (8.9)

 Warfarin

6958 (6.2)

6009 (9.5)

*Comorbid conditions identified from the presence of ICD-9 diagnosis codes in medical encounters during the year prior to initiation of diabetes treatment (Appendix Table 4 for ICD-9 codes)

HDL cholesterol, LDL cholesterol, and hemoglobin A1c missing in 8%, 12%, and 12%, respectively

Glucose-Lowering Medication Use

In 2004, 33,685 individuals initiated metformin (52.4%) or sulfonylurea (47.6%) monotherapy (Appendix Table 5). The proportion of metformin initiators increased during each year of the study, reaching 74.9% in 2009. The average duration of initial monotherapy among metformin and sulfonylurea initiators was 1.7 years for both groups (Table 2). A similar proportion of metformin and sulfonylurea initiators used a second glucose-lowering medication during follow-up (22.6 and 28.8%, respectively).
Table 2

Glucose-Lowering Medication Use among Initiators of Metformin and Sulfonylurea Monotherapy, Veterans Health Administration, 2004–2009

 

Metformin

monotherapy

N = 111,781

Sulfonylurea

monotherapy

N = 63,515

Duration of initial monotherapy treatment, mean years (SD)

1.7 (1.4)

1.7 (1.4)

Duration of initial monotherapy treatment, median years (IQR)

1.3 (0.6–2.5)

1.3 (0.6–2.5)

Maximum duration of initial monotherapy, years

6.2

6.2

Subjects with second glucose-lowering medication added*, n (%)

25,305 (22.6)

18,267 (28.8)

Type of second glucose-lowering medication added, n (%)

 Glipizide

11,531 (45.6)

1364 (7.5)

 Glyburide

8428 (33.3)

270 (1.5)

 Insulin

3783 (15.0)

3984 (21.3)

 Metformin

11,277 (61.7)

 Other

448 (1.8)

529 (2.9)

 Rosiglitazone

1115 (4.4)

1058 (5.8)

*Patients for whom an additional glucose-lowering medication was started beyond the study-defined time interval of medication use were considered to have switched to monotherapy with a different medication and were not included in this table

Primary Analyses

Unadjusted mortality rates were substantially lower for metformin initiators than for sulfonylurea initiators across all categories of eGFR (Appendix Table 6). In the primary analysis, adjusted for all measured potential confounding factors, metformin monotherapy initiation was associated with a significantly lower risk of mortality than sulfonylurea monotherapy initiation among the overall study population (HR 0.64, 95% CI 0.60–0.68; Table 3). Metformin use was associated with lower mortality in all eGFR categories, and the 95% CIs excluded a HR of 1 for all eGFR categories except 30–44 mL/min/1.73 m2. There was strong statistical evidence for an overall interaction between treatment group and eGFR category (p = 0.003), and the lowest mortality risk associated with metformin was observed in the highest eGFR category (≥90 mL/min/1.73 m2). Among individuals with eGFR of 45–59 mL/min/1.73 m2, the HR was of diminished magnitude but still significantly associated with lower mortality risk (HR 0.80, 95% CI, 0.71–0.91; interaction p < 0.001). In sensitivity analyses using intention-to-treat and complete-case approaches, the magnitudes of the HRs within each eGFR category were similar to those from the primary analysis, but the statistical evidence for interaction by eGFR category was weaker (Appendix Table 7).
Table 3

Association between Initiation of Metformin or Sulfonylurea Monotherapy and Mortality among Veterans by eGFR Category, Veterans Health Administration, 2004–2009

Metformin vs. Sulfonylurea

HR (95% CI)*

Interaction P value

Absolute mortality rate difference (95% CI)

Overall

0.64 (0.60–0.68)

−4.8 (−5.6, −4.0)

eGFR (mL/min/ 1.73m2)

 ≥ 90

0.59 (0.50–0.70)

Reference

−3.0 (−4.4, −1.5)

 60–89

0.65 (0.60–0.71)

0.07

−4.3 (−5.4, −3.2)

 45–59

0.80 (0.71–0.91)

<0.001

−3.4 (−5.4, −1.3)

 30–44

0.72 (0.51–1.01)

0.20

−12.1 (−19.0, −5.2)

 

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio

*Includes only monotherapy users who received a refill within the time frame compatible with 80% adherence, as described in the text. Adjusted for the baseline covariates listed in Table 1, as well as Veterans Integrated Service Network (VISN). For those missing HDL, LDL, or A1c values, multiple imputation (n = 50) was conducted

Per 1000 person-years. Complete-case analysis excluded subjects with missing data on HDL cholesterol, LDL cholesterol, or hemoglobin A1c. Adjusted for the baseline covariates listed in Table 1, as well as Veterans Integrated Service Network (VISN)

Secondary Analyses

The differences between mortality rates for metformin initiators and sulfonylurea initiators were similar in eGFR categories ≥90 mL/min/1.73m2 (3.0 fewer deaths/1000 person-years; 95% CI, 1.5–4.4), 60–89 mL/min/1.73m2 (4.3 fewer deaths/1000 person-years; 95% CI, 3.2–5.4), and 45–59 mL/min/1.73m2 (3.4 fewer deaths/1000 person-years; 95% CI 1.3–5.4; Table 3). In eGFR category 30–44 mL/min/1.73m2, the rate difference was substantially greater (12.1 fewer deaths/1000 person-years; 95% CI, 5.2–19.0).

Within each eGFR category, the HRs for metformin versus sulfonylurea treatment were similar across subgroups defined by age, BMI, presence of prior cardiovascular disease, and prior heart failure (Figure 2; Appendix Table 8). There was statistical evidence of an interaction by prior cardiovascular disease (p = 0.01); within eGFR categories ≥90, 60–89, and 45–59 mL/min/1.73m2, HRs were higher among persons with prior cardiovascular disease than among those without prior cardiovascular disease. In addition, there was weak statistical evidence of an interaction by age (75 years threshold; p = 0.04); within eGFR categories 60–89, 45–59, and 30–44 mL/min/1.73m2, the mortality HRs for the comparison of metformin with sulfonylurea treatment were higher among persons aged ≥75 years than among those <75 years. Unadjusted Kaplan–Meier curves overall and by eGFR category showed results consistent with the primary analyses (Appendix Figures 4 and 5).
Figure 2

Association between initiation of metformin or sulfonylurea monotherapy and mortality among Veterans by eGFR category in subgroups, Veterans Health Administration, 2004–2009. Abbreviations: BMI, body mass index; CHF, congestive heart failure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate. Adjusted for the baseline covariates listed in Table 1.

DISCUSSION

In this large national cohort of Veterans with type 2 diabetes and CKD who initiated glucose-lowering therapy, metformin monotherapy was associated with substantially lower mortality than monotherapy with a sulfonylurea. The absolute difference in mortality rates appeared greatest among patients with the most severe CKD (eGFR 30–44 mL/min/1.73m2), who also suffered the highest overall burden of mortality. The primary results were robust to sensitivity analyses that evaluated assumptions about medication use assessment during follow-up and missing data. Subgroup analyses did not identify strong effect modifiers of these associations, although there was some evidence that the health benefits associated with metformin in this population may be slightly reduced among those with pre-existing cardiovascular disease and those aged 75 years and older.

A recent systematic review of health outcomes related to metformin use in populations with type 2 diabetes and contraindications to treatment concluded that metformin use in patients with moderate CKD was associated with improvements in key clinical outcomes. This finding was based, in part, on results from two observational studies that reported mortality by CKD stage, but which were rated as having a moderate risk of bias.12 Ekstrom et al. conducted an observational cohort study of 51,675 men and women with type 2 diabetes registered in the Swedish National Diabetes Register and regularly prescribed glucose-lowering treatment.7 They found that the use of metformin compared with any other glucose-lowering treatment was associated with a significantly reduced risk of mortality among 7177 patients with an eGFR of 45–59 mL/min/1.73 m2 (HR 0.87, 95% CI 0.77–0.99), but not among 2146 patients with an eGFR of 30–44 mL/min/1.73 m2 (HR 1.02, 95% CI 0.84–1.24).7 Roussel et al. conducted an observational study assessing whether metformin use was associated with a difference in mortality compared to non-metformin regimens in 19,691 patients with diabetes and advanced cardiovascular disease; among 4960 patients with an eGFR of 30–60 mL/min/1.73 m2, metformin use compared with non-use was associated with a reduced risk of death (HR 0.64, 95% CI 0.48–0.86).10 These studies had important methodological limitations: both lacked a well-defined comparator treatment group, and the study by Roussel evaluated prevalent rather than new users of metformin. In contrast, our study employed a new-user design and compared metformin initiators with sulfonylurea initiators in a large unselected population with type 2 diabetes and CKD, and we found that the use of metformin versus a sulfonylurea was associated with mortality benefits among all strata of eGFR evaluated, including persons with eGFR of 30–44 mL/min/1.73m2.

In the absence of clinical trial data evaluating the safety and effectiveness of metformin specifically in CKD, regulatory bodies, professional societies, and clinicians must rely on well-conducted observational studies and meta-analyses.2 Our study provides evidence in support of the initiation of metformin treatment for type 2 diabetes among persons with an eGFR of 45 mL/min/1.73m2 or greater, consistent with recent recommendations from the FDA and other experts.2 , 4 Moreover, our study provides new evidence that initiating metformin treatment may be beneficial among persons with an eGFR of 30–44 mL/min/1.73m2, a group in whom initiation of metformin therapy is not currently recommended.4 If our findings are replicated in independent populations, the recommendation to restrict metformin treatment among persons with moderately–severely reduced eGFR may require re-examination.

Several biological mechanisms have been proposed by which metformin might reduce mortality: decreasing insulin and IGF-1 signaling, mTOR inhibition, reducing levels of reactive oxygen species, lowering inflammation, reducing DNA damage, and activating AMP-activated protein kinase (AMPK).23 Metformin has been described as a caloric restriction mimetic based partly on its effect on AMPK, and this drug is now being studied to examine its potential anti-aging effects. A systematic review reported that patients with diabetes taking metformin had significantly lower mortality and a lower risk of cardiovascular disease than patients taking non-metformin therapies.23 If one of the pathways through which metformin reduces mortality is in decreasing the incidence or progression of atherosclerotic cardiovascular disease, then a reduced effect among persons with pre-existing cardiovascular disease would be expected. Our findings from subgroup analyses are consistent with this reasoning.

Our study has important strengths. First, this is the largest study of the use of metformin versus sulfonylureas in patients with type 2 diabetes and CKD. With 175,296 Veterans in the overall sample, we were able to achieve a sample size sufficient to evaluate metformin effects within narrow categories of eGFR. Second, the new-user design minimizes the confounding and selection biases that arise from evaluating prevalent users, which represent a heterogeneous cross-section of patients with varying severity and duration of diabetes, and may be depleted of persons who experienced early adverse effects or treatment failures.24 Third, we used rich VHA electronic health data to assess and adjust for important potential confounding factors. Fourth, in contrast to prior studies, we used a clinically meaningful direct comparison of metformin to a single glucose-lowering drug category (i.e., sulfonylureas), which reflects a well-defined clinical decision. Finally, glucose-lowering therapy use was assessed over time so that we were able to censor persons who became non-adherent to their initial treatment group.

Our study also has limitations. First, we did not have dosage information to assess a potential dose–response association. Second, since the period when this study was conducted, several new classes of glucose-lowering drugs have been approved,25 and large post-marketing randomized controlled trials suggest that some of these newer therapies may prevent cardiovascular complications.26 However, to evaluate the relative mortality risks associated with metformin versus a similarly used treatment, it was necessary to conduct these analyses during a time when there was greater clinical equipoise about the initial selection of glucose-lowering treatment for type 2 diabetes, before the widespread adoption of the recommendation to start treatment for type 2 diabetes with metformin. This analysis would not have yielded credible results if more recent data had been used. Third, although we adjusted for multiple covariates associated with mortality and metformin use, we cannot exclude the possibility of residual confounding by indication, given the observational design of this research. Fourth, while we controlled for VISN as a measure of potential regional variation within the VA, we were not able to control for provider characteristics associated with prescribing metformin versus sulfonylureas. Fifth, we were unable to determine the specific causes of CKD. Type 2 diabetes is the leading cause of CKD in the US.27 However, our study assessed eGFR prior to the initiation of diabetes treatment and early in the course of diabetes; therefore, CKD in this cohort was most often from other causes. For example, approximately 77% of the cohort had hypertension, a major risk factor for CKD. Lastly, the study population consisted mostly of older male Veterans, so the results may not generalize to women or younger populations.

In conclusion, our study suggests that initiation of treatment for type 2 diabetes with metformin versus a sulfonylurea in individuals with CKD is associated with substantially lower mortality, in terms of both relative and absolute risk reductions. The lower mortality associated with metformin was observed even among individuals with moderately–severely reduced eGFR (30–44 mL/min/1.73m2), a population in which evidence regarding the health benefits of metformin is limited. These findings, together with results from previous studies, support the FDA’s guidance to consider metformin initiation among individuals with an eGFR of 45–59 mL/min/1.73m2, and suggests that metformin initiation may be beneficial among persons with even more severe CKD. Given the number of glucose-lowering drugs available, further comparative effectiveness research is needed to guide prescribing practices, especially for high-risk patient populations.

Notes

Funding Source

Dr. Floyd received financial support from the National Heart, Lung, and Blood Institute (NHLBI grant K08HL116640). The views expressed by Drs. Boyko and Smith are theirs alone and do not necessarily represent the views of the Department of Veterans Affairs or the United States Government.

Compliance with Ethical Standards

Conflict of Interest

All authors declare that they have no relevant financial interests, activities, relationships, or affiliations, or other potential conflicts of interest to report.

References

  1. 1.
    American Diabetes Association. Standards of medical care in diabetes—2017: Summary of revisions. Diabetes Care. 2017;40:S4–5.CrossRefGoogle Scholar
  2. 2.
    Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668–75.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Flory JH, Hennessy S. Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on Food and Drug Administration contraindications. JAMA Intern Med. 2015;175:458–9.CrossRefPubMedGoogle Scholar
  4. 4.
    U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed May 15, 2017.
  5. 5.
    Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316:602–10.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4:53–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2(4).  https://doi.org/10.1136/bmjopen-2012-001076.
  8. 8.
    Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Association between first-line monotherapy with sulfonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. 2014;16:957–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Weir MA, Gomes T, Mamdani M, et al. Impaired renal function modifies the risk of severe hypoglycemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrol Dial Transplant. 2011;26:1888–94.CrossRefPubMedGoogle Scholar
  12. 12.
    Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med. 2017;166:191–200.CrossRefPubMedGoogle Scholar
  13. 13.
    Hampp C, Borders-Hemphill V, Money DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014;37:1367–74.CrossRefPubMedGoogle Scholar
  14. 14.
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26:S33–50.CrossRefGoogle Scholar
  15. 15.
    Floyd JS, Blondon M, Moore KP, Boyko EJ, Smith NL. Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of Veterans with diabetes. Pharmacoepidemiol Drug Saf. 2016;25:467–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Wheeler S, Moore K, Forsberg CW, et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia. 2013;56:1934–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 2: definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3:63–72;  https://doi.org/10.1038/kisup.2012.65 CrossRefGoogle Scholar
  19. 19.
    Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12:462–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Schafer JL. Analysis of Incomplete Multivariate Data. Boca Raton, FL: Chapman & Hall/CRC; 1997.CrossRefGoogle Scholar
  21. 21.
    Danaei G, Rodriguez LA, Cantero OF, Logan R, Hernán MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22:70–96.CrossRefPubMedGoogle Scholar
  22. 22.
    Bansal N, Katz R, Robinson-Cohen C, et al. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies. JAMA Cardiol. 2017;2:314–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and disease of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. Ageing Res Rev. 2017;40:31–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Flory JH, Ukena JK, Floyd JS. Novel anti-glycemic drugs and reduction of cardiovascular risk in diabetes: expectations realized, promises unmet. Curr Atheroscler Rep. 2016;18:79.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care. 2016;39:738–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31:2608–17.CrossRefPubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2017

Authors and Affiliations

  • Zachary A. Marcum
    • 1
  • Christopher W. Forsberg
    • 2
  • Kathryn P. Moore
    • 2
  • Ian H. de Boer
    • 3
    • 4
    • 5
  • Nicholas L. Smith
    • 2
    • 4
    • 6
    • 7
  • Edward J. Boyko
    • 2
    • 3
    • 8
  • James S. Floyd
    • 3
    • 4
    • 6
    • 7
  1. 1.Department of Pharmacy, School of PharmacyUniversity of WashingtonSeattleUSA
  2. 2.Seattle Epidemiologic Research and Information CenterVA Puget Sound Health Care SystemSeattleUSA
  3. 3.Department of MedicineUniversity of WashingtonSeattleUSA
  4. 4.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  5. 5.Kidney Research InstituteUniversity of WashingtonSeattleUSA
  6. 6.Cardiovascular Health Research UnitUniversity of WashingtonSeattleUSA
  7. 7.Kaiser Permanente Washington Health Research InstituteKaiser Permanente WashingtonSeattleUSA
  8. 8.General Medicine ServiceVA Puget Sound Health Care SystemSeattleUSA

Personalised recommendations